MedTrace Logo

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

NCT04176354 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 813

Last updated 2024-08-23

Study results available
· View outcomes & findings →

Summary

A retrospective observational analysis of de-identified Flatiron Health Analytic Database to describe patient characteristics, treatment patterns and effectiveness of Palbociclib + AI as first-line therapy in HR+/HER2- metastatic breast cancer (MBC) in the US clinical practices.

Conditions

Interventions

DRUG

Palbociclib + an aromatase inhibitor

Palbociclib + an aromatase inhibitor therapy

DRUG

Palbociclib + Letrozole

Palbociclib + Letrozole therapy

DRUG

Letrozole

Letrozole monotherapy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2019-09-27
Completion
2019-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176354 on ClinicalTrials.gov